Phase 3Completed
Interleukin-2 Plus Histamine Dihydrochloride in Treating Patients With Acute Myeloid Leukemia
Multi-Center, Randomized Open-Label Study to Evaluate the Safety and Efficacy of Immunotherapy With Subcutaneous Maxamine (Histamine Dihydrochloride) Plus Proleukin (Interleukin-2) Versus No Treatment (Standard of Care) in Patients With Acute Myeloid Leukemia in First or Subsequent Complete Remission (CR)
- Sponsor
- Maxim Pharmaceuticals (Industry)
- Enrollment
- 360 planned
- Conditions
- Leukemia
- Interventions
- aldesleukin; histamine dihydrochloride
- Ages
- adults, older adults
- Registry
- NCT00003991
Full record on ClinicalTrials.gov
From the registry
RATIONALE: Interleukin-2 may stimulate a person's white blood cells to kill acute myeloid leukemia cells. Histamine dihydrochloride may prolong remission and reduce the risk of relapse in patients with acute myeloid leukemia in remission. PURPOSE: Randomized phase III trial to determine the effectiveness of interleukin-2 plus histamine dihydrochloride in treating patients who have acute myeloid leukemia that is in remission following previous therapy.
History
Last registry update
Study completion
Registered
Started